Pregnant women with hepatitis b: which drug is safer?
NCT ID NCT07668934
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at two antiviral drugs, TAF and TDF, in pregnant women with chronic hepatitis B. It aims to see which one better controls the virus and keeps the mother's liver healthy without harming the baby. About 816 women in early or middle pregnancy will take one of the drugs until delivery and be followed for outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF)
What this could lead to
If successful, this could show that TAF is a safer option for pregnant women with hepatitis B, reducing liver issues and protecting the baby from infection.
What could go wrong
This is a phase 4 study, but results may not apply to all women. Risks include potential side effects for mother or baby, and the study does not aim to cure hepatitis B.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Third Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China